Diplomat Pharmacy (DPLO) Tops Q1 EPS by 4c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Diplomat Announces 1st Quarter Financial Results
May 8, 2017 4:20 PM EDTFLINT, Mich., May 8, 2017 /PRNewswire/ --Â Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended March 31, 2017. Â All comparisons, unless otherwise noted, are to the quarter ended March 31, 2016.
First Quarter 2017 Highlights include:
Revenue of $1,079 million, compared to $996 million, an increase of 8% Total prescriptions dispensed of 220,000, compared to 232,000 Gross margin of 7.9% versus 8.0% Gross profit per prescription dispensed of $383, compared to $332 Net income attributable to Diplomat of $4.4... More